Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:
|
Afatinib
|
<5
|
|
Alectinib
|
<5
|
|
Amivantamab
|
NIL
|
|
Atezolizumab monotherapy
|
<5
|
|
Atezolizumab with chemotherapy
|
<5
|
|
Brigatinib
|
NIL
|
|
Ceritinib
|
NIL
|
|
Crizotinib
|
NIL
|
|
Dacomitinib
|
NIL
|
|
Dabrafenib with Trametinib
|
<5
|
|
Durvalumab
|
<5
|
|
Erlotinib
|
NIL
|
|
Gefitinib
|
<5
|
|
Lorlatinib
|
NIL
|
|
Mobocertinib
|
NIL
|
|
Nintedanib with Docetaxel
|
<5
|
|
Nivolumab
|
<5
|
|
Osimertinib
|
9
|
|
Pembrolizumab monotherapy
|
45
|
|
Pembrolizumab with chemotherapy
|
33
|
|
Pemetrexed with Carboplatin/Cisplatin
|
5
|
|
Pralsetinib
|
NIL
|
|
Selpercatinib
|
NIL
|
|
Sotorasib
|
<5
|
|
Tepotinib
|
NIL
|
|
Vinorelbine with Carboplatin/Cisplatin
|
9
|
|
Any other active systemic anti-cancer therapy (SACT)
|
13
|
|
Palliative care only
|
Data not available
|
Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:
· Atezolizumab monotherapy – NIL
· Atezolizumab with chemotherapy – <5
· Durvalumab – NIL
· Nivolumab – NIL
· Osimertinib – NIL
· Pembrolizumab (Keytruda) Mono – NIL
· Pembrolizumab (Keytruda) with Chemotherapy – NIL
· Tepotinib – NIL
· Other active systemic anti-cancer therapy (SACT) – NIL
· Palliative care only – NIL
Q3. Do you participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each trial and the number of patients taking part.
ICI Genetics - Identification of genetic factors that predispose to immune checkpoint inhibitor toxicity. This is an observational cross cutting study which includes patients with NSCLC. There are 5 participants, but it is not possible to say whether these are NSCLC or other.
